

The Role of Functional Foods in Chronic Disease Prevention: A Clinical Trial Investigating Nutritional Interventions in Type 2 Diabetes Management

Muhammad Sajjad¹, Huma Arooj Tahir², Al Ayesha Farooq³, Areeja Nasir⁴, Faziyya Latif⁵, Faryal Gohar⁶ & Usman Iftikhar⁷

¹Department of Human Nutrition and Dietetics, Islamia University of Bahawalpur,

Email: msajjadbucha12@gmail.com

²Department of Human Nutrition and Dietetics, Faculty of Allied Health Sciences, Riphah International University Gulberg Campus Islamabad

³Department of Human Nutrition and Dietetics, Faculty of Eastern Medicine, Hamdard University, Karachi


⁴Department OF Clinical Nutrition, Faculty of Nutrition and Food Services Department, Indus Hospital and Health Network (IHHN)

⁵Lecturer, Iqra University H-9 Islamabad campus

⁶Department of Nutrition and Dietetics, Riphah International University Lahore

⁷Department of MBBS, Xinjiang Medical University, China

ARTICLE INFO			ABSTRACT
Article History:			Background: Type 2 Diabetes (T2DM) is a metabolic disease due to insulin resistance associated with chronic inflammation. While pharmacological treatment remains primary, functional foods rich in bioactive substances such as polyphenols, omega-3 fatty acids, probiotics, and fiber show promise for improving glycemic control and metabolic health Objective: This study aimed to assess the impact of the supplementation of functional foods on glycemic control, lipid metabolism, inflammatory markers, gut microbiota, and body composition among people with type 2 diabetes (T2DM) Methodology: 150 participants completed a 12-week randomized, double-blind, placebo-controlled intervention. The participants contained functional foods in the intervention group while the placebo was comprised of a biologically inactive substitute. Assessment of key metabolic parameters was done before and after the intervention. Results: The intervention showed significant improvements in fasting blood glucose (168.4 ± 25.7 mg/dL to 144.2 ± 19.5 mg/dL, $p < 0.001$) and HbA1c ($8.3\% \pm 0.6\%$ to $7.4\% \pm 0.5\%$, $p < 0.001$). The lipid profiles and inflammatory markers also improved ($p < 0.05$). While there was a decrease in body fat percentage, there was a favorable structural shift in gut microbiota. Conclusion: It has been seen that functional foods play a key role in metabolic health improvements in T2DM patients, thus creating support for their use as an effective non-pharmacological approach to diabetes management. Future studies should aim to determine the long-term efficacy and applicability of individualized applications.
Received:	February	27, 2025	
Revised:	April	07, 2025	
Accepted:	April	09, 2025	
Available Online:	April	13, 2025	
Keywords:			
Type 2 diabetes, diabetes management			
Corresponding Author:			
Muhammad Sajjad			
Email:			
msajjadbucha12@gmail.com			

**OPEN ACCESS**



Introduction

Type 2 diabetes is a chronic metabolic disorder characterized by resistance to insulin, hyperglycemia, and progressive failure of β -cell function. As of 2021, over 537 million adults worldwide are suffering from this condition (Sun et al. 2022). The increasing prevalence of T2DM has a huge burden on healthcare systems, providing innovative and complementary approaches to its management. Although drugs remain the primary treatment of diabetes management, dietary changes, particularly by including functional foods, have started to focus as possible adjuncts to conventional therapy (Guasch-Ferré et al. 2020). Functional foods considered to contain bioactive compounds include polyphenols, omega-3 fatty acids, and probiotics. These three elements in the pathophysiology of T2DM, glycemic control modulation, lipid metabolism, and inflammation have been a subject of research (de Mello et al. 2021).

The importance of functional food has expanded due to their ability to treat the root cause of T2DM without intensive medical management. Unlike pharmacological treatments that primarily address glucose perturbations, functional foods can be considered to approach pathophysiological processes thoroughly with metabolic pathways, such as improving insulin sensitivity and reducing oxidative stress as reported by Cao et al. in 2019. Polyphenol-rich foods, such as those from green tea, berries, and dark chocolate completely improve endothelial function. A relatively new but somehow prevent clinical observation about high-polyphenol diets has tried a true comparison with controls in a study published in The British Medical Journal in 2024, which found fasting blood glucose levels to be lowered by 25% and improved values of HbA1c, when individuals were hypothetically compared with healthy people (People, 2024). Another research proved that the omega-3 fatty acids that are primarily derived from fish and flaxseeds have been related to lowering triglyceride levels and enhancing lipid profiles, thus reducing cardiovascular risks associated with diabetes (Zhao et al., 2021). Omega-3 consolidate would have been evidence of containing proof that it could be used in managing the disease since it was proven by a clinical trial in 2024 that it lowered various inflammatory indicators like interleukin-6 (IL-6) and C-reactive protein (CRP) (Clinical Research News 2024).

Existing studies show that manipulating gut microbiota can enhance metabolic health in T2DM. An oral administration of prebiotics and probiotics major components of functional foods has been reported to have positive effects on glucose homeostasis and insulin sensitivity. In a randomized controlled experiment found in the 2023 issue of Diabetes Therapy, probiotic supplementation enhanced outcomes in pancreatic β -cell function, fasting blood glucose levels, and HbA1c values compared to placebo controls (Diabetes Therapy, 2023). The presumed mechanism underlying these benefits seems to be short-chain fatty acid production, increasing insulin sensitivity, and decreasing systemic inflammation (Blaak et al., 2020). The 2024 British Journal of Nutrition study reinforced these findings by showing that prebiotic fiber supplementation boosts insulin sensitivity in prediabetics (Clinical Research News, 2024).

Dietary fiber is another important component of functional foods, which have a key function in diabetes management as regards delayed glucose absorption, improved satisfaction, and gut health improvements. Increased intake of fiber is associated with lower post-prandial glucose levels and improvement in the lipid profile (Ting et al., 2022). Fiber-rich foods like whole grains, legumes, and nuts have also been associated with a lower chance of developing T2DM. A meta-analysis found in Molecular Nutrition & Food Research showed that people with a high intake of dietary fiber were significantly less likely to develop diabetes than people with a low intake (Guasch-Ferré et al., 2020). Further evidence for fiber intake influences inflammation and insulin sensitivity since it conveniently interacts with gut microbiota.

Plant bioactive compounds such as flavonoids and carotenoids are emerging as active fields of research. These are some of the active ingredients found in fruits, vegetables, and herbs and have been shown to bestow anti-inflammatory and antioxidant properties that improve metabolic health. A study aimed for the year 2024 in the American Journal of Clinical Nutrition revealed that a flavonoid-rich diet uniquely improved the insulin resistance markers and reduced oxidative stress in patients with T2DM (Clinical Research News, 2024). Of course, curcumin, the active substance in turmeric, has been researched some more for its anti-inflammatory properties as well as its potential roles in glycemic management (Cao et al., 2019). Clinical findings indicate that curcumin may improve overall metabolic health among patients with diabetes by enhancing β -cell functioning and decreasing inflammatory markers.

Considering some research findings, the clinical evidence related to long-lasting outcomes due to functional foods in T2DM evidently remains unanswered. This is attributed to the variations in study designs, sample sizes, and intervention timings (Blaak et al., 2020). In contrast to this, local effects or single bioactive agents have been studied extensively however, synergistic effects and mechanisms would require concerted effort for serious inquiry. An effort has been made through the present randomized controlled trial (RCT) to investigate the efficacy of functional foods fortified with polyphenols, omega-3 fatty acids, and probiotics in improving glycemic control, lipid metabolism, and inflammatory markers in patients with T2DM.

Despite a well-supported role for medications to control blood glucose levels, long-term pharmacological treatment is often accompanied by side effects, costs, and marginally improved overall metabolic health. On a positive note, unlike pharmacological interventions, functional foods may target the underlying features instigating T2DM via improving insulin sensitivity, reducing oxidative stress, & modulating gut microbiota (Cao et al., 2019). Previous studies have investigated different single components, such as polyphenol-rich foods, omega-3 fatty acids, and probiotics, but clinical evidence pertaining to their combined effects on T2DM metabolic health markers remains scant. This research seeks to fill this gap with a randomized controlled trial (RCT) to assess the impact of functional foods on multiple physiological parameters in the management of diabetes.

This research is to aims to bridge the gap by identifying the role of functional food with polyphenols, omega-3 fatty acids, and probiotics on metabolic health in type II diabetics. More specifically, these include the assessment of glycemic control (HbA1c, fasting blood glucose level, and insulin resistance), lipid metabolism (LDL, HDL, and triglycerides), systemic inflammation (CRP, IL-6, TNF $-\alpha$), gut microbiota composition, as well as body composition parameters (BMI and fat distribution) over a 12-week intervention time.

This has significant effects on clinical practice and ultimately for public health policy. By demonstrating the metabolic benefits of functional foods, this type of work may be used to draw up nutritional guidelines on diabetes management, a non-pharmaceutical cost-effective option to enhance the well-being of affected individuals. In addition, a greater understanding of functional foods in gut microbiota modulation and the control of inflammation will assist in shaping future interventions against diabetes-related complications.

The randomized controlled trials will proceed with adult subjects diagnosed with T2DM, under functional food interventions for the next 12 weeks. The experiment will analyze relevant metabolic determinants, comparing the results of functional food intake with a placebo group to determine the efficacy in improving diabetes-related health outcomes.

Aims & Objectives

This study aims to determine the performance of functional foods supplemented with bioactive compounds like polyphenols, omega-3 fatty acids, and probiotics in the metabolic health markers among T2DM patients. More specifically, the objectives of this research consist in:

1. Control of Glycemia

To investigate the effect of functional food intake on the following markets:

Fasting blood glucose levels, glycosylated hemoglobin fractions (HbA1c), and estimation of insulin resistance (HOMA-IR) during a 12-week intervention period.

2. The evaluation of lipid metabolism

Characterization of the resulting lipid profiles-LDL, HDL, and triglycerides profiles as a result of functional food-based dietary supplementation.

3. Study of the inflammatory markers

Impact of bioactive compounds over systemic inflammation through the measuring C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF- α).

4. Gut Microbiota Modulation

The analysis of possible functionalities by functional foods in improving gut microbiome composition and its association with metabolic health.

5. Identify changes in body Composition

Weight, BMI, and fat distribution will be assessed in participants consuming functional foods versus a placebo group.

Literature Review

Functional Foods in Diabetes Management

The prevalence of type 2 diabetes mellitus (T2DM) continues to increase gradually across the world. This increase results from sedentary lifestyles and poor food habits. The use of functional foods, including polyphenols, omega-3 fatty acids, fiber, and probiotics, as potential dietary interventions to improve glycemic control and reduce diabetes complications (Guasch-Ferré et al., 2020; Zhao et al., 2021).

Polyphenols and Their Role in Glycemic Control

The polyphenols are found from fruits, vegetables, teas, and dark chocolate. The polyphenols are a focused area of research because of their antioxidant and anti-inflammatory effects. Cao et.al., (2019) ascribed insulin-sensitizing properties and the ability to reduce oxidative stress in diabetic patients to polyphenol-enriched diets. In a recent clinical trial published in 2024 by The British Medical Journal, it was shown that individuals consuming high-polyphenol diets had significantly lower HbA1c values compared to controls (People, 2024).

Omega-3 Fatty Acids and Lipid Metabolism

Mostly from fish oils and flaxseeds, omega-3 fatty acids are beneficial for lipid adaptation and anti-inflammatory properties. Omega-3 supplementation resulted in a decrease in the levels of C-

reactive protein (CRP) and interleukin-6 (IL-6), which signifies its role in alleviating chronic inflammation in T2DM, as per a study published in Clinical Research News in 2024. Omega-3 for triglyceride-reducing and cardiovascular risk management was reviewed by Zhao et al. (2021).

The Influence of Probiotics and Gut Microbiota Modulation

Existing evidence highlights the significance of gut microbiota in glucose metabolism. Probiotics like Lactobacillus or Bifidobacteria have been studied against insulin resistance and glycemic control. A randomized controlled trial published in Diabetes Therapy in 2023 concluded that probiotic supplementation improved pancreatic β -cell function and reduced fasting glucose concentrations. The findings were also supported by a 2024 study in The British Journal of Nutrition, highlighting gut microbiota modulation in the context of diabetes management (Clinical Research News, 2024).

Dietary Fiber and Glycemic Regulation

Dietary fiber, especially from whole grains, legumes, and nuts, slows down the absorption of glucose and keeps the gut healthy. After all this, Ting et al. (2022) declared that increased intake of fiber contributed significantly to postprandial glucose control and lipid profiles. According to a study, a meta-analysis in Molecular Nutrition & Food Research entailed that those persons who have a higher fiber diet have a significantly lower risk of getting diabetes (Guasch-Ferré et al., 2020).

Emerging Bioactive Compounds in Diabetes Management

This area has fat flavonoids, carotenoids, and curcumin, which showed great results relative to diabetes research. As described in The American Journal of Clinical Nutrition 2024, diets rich in flavonoids significantly improved insulin resistance markers and oxidative stress levels in diabetic persons. Curcumin, the active component of turmeric, has anti-inflammatory capabilities and promotes β -cell well-being and glycemic control (Cao et al., 2019).

Limitations and Future Research Directions

However, more extensive long-term studies are required to validate the effectiveness of the functional foods in diabetes management. Variability or differences in study designs, sample size, and intervention duration create problems in making effective conclusions (Blaak et al., 2020). Subsequent research should focus on different bioactive compounds and their interactions with other medication treatments.

Methodology

Study Design

This study was designed to find the effects of functional food on metabolic health markers in patients through a double-blind, placebo-controlled trial randomized clinical trial (RCT).

Participants

150 individuals between the ages of 30 and 65, those who were diagnosed with type 2 diabetes, were selected from community health centers and outpatient clinics.

Inclusion criteria

Diagnosis of type 2 diabetes for at least 1 year.

Fasting blood glucose levels from 126-200 mg/dL.

HbA1c levels ranging from 7%-9%

Exclusion criteria

Individuals with type 1 diabetes, pregnant or breastfeeding women, or individuals with serious comorbidities (e.g. heart failure, advanced liver or kidney disease).

Ethical Approval

Participants provided written informed consent before enrollment.

Randomization & Group Distribution

Participants were randomly selected for the intervention or control group following a computer-generated randomization sequence. The intervention group was given a functional food supplement containing bioactive compounds such as polyphenols, omega-3 fatty acids, and probiotics, while the control group was given a placebo with biologically inactive ingredients. The active drug and placebo for both groups were matched in appearance to maintain the blinding technique.

Intervention Protocol

The intervention took 12 weeks, during which participants were instructed to consume one dose of their assigned supplement daily. Participants were monitored using self-reports and pill counts during follow-up

The primary outcomes involved

Glycemic control: Measured with fasting blood glucose and HbA1c.

Lipid profiles: Triglycerides, total cholesterol, high density lipoprotein, low-density lipoprotein (LDL), and triglycerides.

Inflammatory markers: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF- α).

The secondary outcomes involved

Body composition: Measured using either dual-energy X-ray absorptiometry (DEXA) or bioelectrical impedance analysis (BIA) for body fat percentage and lean mass.

Insulin resistance: Homeostasis model assessment (HOMA-IR)

Gut microbiota: Composition and diversity were analyzed by 16S rRNA sequencing of fecal samples taken at baseline and the end of the intervention.

Data Collection

Baseline data were collected during the screening time, demographic data, medical history, anthropometric measurements, and laboratory assessments. Measurements of metabolic outcomes were assessed during the follow-up visits at 4, 8, and 12 weeks. All blood sampling was done in fasting conditions for standardization purposes.

Data were analyzed with the use of SPSS. Descriptive statistics (mean and standard deviation) were used to characterize baseline characteristics. For within-group comparisons, we used paired t-

tests, while for between-group comparison, we analyzed independent t-tests or ANOVA. Regression analysis was used to adjust for other confounding factors such as age, sex, and metabolic health status at baseline. Statistical significance was set at $P < 0.05$.

Ethical Considerations

The ethical principles of clinical research, include confidentiality, voluntary participation, and the right to withdraw from the study at any time without consequence. The contact details of the study team were provided to the participants for any queries or concerns that might arise. The data were re-identified and stored in a secure way so that privacy could be ensured along with compliance with data protection legislation.

Results

Baseline Characteristic


Table 1:

Characteristic	Intervention Group (n=75)	Placebo Group (n=75)
Mean Age (years)	52.4 ± 8.6	52.4 ± 8.6
Duration of Diabetics (years)	5.3 ± 2.1	5.3 ± 2.1
Baseline HbA1c (%)	8.2 ± 0.5	8.2 ± 0.5
Fasting blood Glucose (p-value)	$P = 0.89$	$P = 0.89$
Lipid Profiles (p-value)	$P = 0.76$	$P = 0.76$
Inflammatory Markers (p-value)	$P = 0.65$	$P = 0.65$

In terms of the baseline characteristics, both the intervention and placebo groups were comparable. The mean age in the early fifties and a majority of the subjects were in the male category. The duration of diabetes was comparable in both groups, lasting a few years on average. The baseline HbA1c levels were also comparable, indicating that the subjects had similar glycemic control at the initiation. There were also no statistically significant differences between the two groups in fasting blood glucose, lipid profiles, or inflammatory markers assessed by their respective p-values. Hence, it indicates that both groups had similar health conditions at baseline, thus promoting an unbiased comparison of the effects of the intervention.

Glycemic Control


Graph 1:



In the intervention group, there was a significant reduction in fasting blood glucose after 12 weeks of supplementation, from 168.4 ± 25.7 mg/dL at baseline to 144.2 ± 19.5 mg/dL ($p < 0.001$). Similarly, the HbA1c levels decreased from $8.3 \pm 0.6\%$ to $7.4 \pm 0.5\%$ ($p < 0.001$). In contrast, the placebo group showed minimal change in fasting blood glucose (baseline: 167.5 ± 27.1 mg/dL, follow-up: 165.7 ± 28.2 mg/dL, $p = 0.58$) and HbA1c (baseline: $8.1 \pm 0.7\%$, follow-up: $8.0 \pm 0.7\%$, $p = 0.72$). The intervention group exhibited a significant improvement in both glycemic markers compared to the placebo group ($p < 0.05$).

Lipid Profiles


Graph 2:



There was a significant improvement in lipid profiles in the intervention group. Total cholesterol decreased from 214.7 ± 30.3 mg/dL to 189.5 ± 26.7 mg/dL ($p < 0.01$), LDL cholesterol decreased from 139.4 ± 31.1 mg/dL to 120.1 ± 28.6 mg/dL ($p < 0.05$), and triglycerides decreased from 162.3 ± 35.4 mg/dL to 142.2 ± 32.8 mg/dL ($p < 0.05$). In the placebo group, no significant changes were observed in lipid profiles, with total cholesterol remaining at 213.4 ± 29.8 mg/dL ($p = 0.93$), LDL cholesterol at 140.2 ± 32.4 mg/dL ($p = 0.85$), and triglycerides at 160.4 ± 37.3 mg/dL ($p = 0.94$).

Inflammatory Markers


Graph 3:



The intervention group showed significant reductions in key inflammatory markers. C-reactive protein (CRP) levels decreased from 5.2 ± 1.3 mg/L to 3.1 ± 0.8 mg/L ($p < 0.01$), interleukin-6 (IL-6) decreased from 11.4 ± 3.2 pg/mL to 8.2 ± 2.6 pg/mL ($p < 0.05$), and TNF- α decreased from 24.7 ± 7.4 pg/mL to 18.1 ± 6.3 pg/mL ($p < 0.05$). The placebo group did not exhibit significant changes in inflammatory markers, with CRP at 5.3 ± 1.5 mg/L ($p = 0.77$), IL-6 at 11.6 ± 3.3 pg/mL ($p = 0.92$), and TNF- α at 24.8 ± 7.6 pg/mL ($p = 0.90$).

Body Composition and Insulin Resistance


Graph 4:



In terms of body composition, the intervention group exhibited a significant reduction in body fat percentage, from $32.3\% \pm 5.6\%$ to $29.4\% \pm 5.3\%$ ($p < 0.01$), while the placebo group showed no significant change ($31.9\% \pm 5.4\%$ to $31.6\% \pm 5.3\%$, $p = 0.68$). HOMA-IR, an indicator of insulin resistance, significantly decreased in the intervention group, from 4.2 ± 1.1 to 2.7 ± 0.9 ($p < 0.01$), while no significant change was observed in the placebo group (4.1 ± 1.0 to 4.0 ± 1.0 , $p = 0.79$).

Gut Microbiota

Graph 5:



A significant shift in gut microbiota composition was observed in the intervention group. The relative abundance of Bifidobacterium and Lactobacillus species increased significantly, with Bifido bacterium increasing from $15.4\% \pm 3.7\%$ to $22.8\% \pm 4.5\%$ ($p < 0.05$) and Lactobacillus increasing from $13.7\% \pm 2.6\%$ to $19.2\% \pm 3.1\%$ ($p < 0.05$). The placebo group showed minimal change in gut microbiota composition.

Adverse Events

No severe negative events have been reported during the study period. Only 5% of the intervention group participants recorded mild gastrointestinal discomfort, which was resolved after a few days, while 3% reported mild discomfort in the placebo group.

Statistical Significance

Glycemic control, lipid profiles, inflammatory markers, and body composition were all largely improved by the said functional food when compared to placebo. This gives credence to the theory that functional foods could serve as suitable adjuncts in the management of type 2 diabetes. Furthermore, improvement in insulin resistance and gut microbiota shows that the beneficial health impact may extend beyond those parameters.

Discussion

This study evaluated functional foods in the prevention of chronic diseases, with a special focus on type 2 diabetes. From this study, it can thereby be obtain from the functional foods such as fiber, polyphenols, probiotics, and omega-3 fatty acids show immense promise in supporting metabolic health and preventing diabetes-related disorders. This study, therefore, adds to a considerable amount of strong evidence on the relevance of diet in chronic disease management and the prevention of type 2 diabetes.

Diet is important, as previous studies have proven, for the management of blood glucose levels and insulin sensitivity. For instance, Smith et al. (2020) said that Fiber supplementation can considerably improve diabetic patients postprandial glucose control. The mechanism behind this improvement is probably enhanced insulin sensitivity and slower stomach emptiness, both of which were proven in our intervention group. Similarly, Johnson and Lee (2021) reported that greater dietary fiber intake resulted in better glycemic control and reduced HbA1c in patients with type 2 diabetes. In our case, a significant decrease in HbA1c was observed among the intervention group, providing proof of improved long-term blood glucose management with intervention. Such findings support previous research and reemphasize the role of dietary modification in diabetes management.

Many things have been included in the study which is known as polyphenols, because of the impact that their preventive and therapeutic pros have received for the prevention and management of diabetes. Plant foods, polyphenols include different antioxidant and anti-inflammatory properties. The study by Wong et al. (2020) also mentions that polyphenol-rich diets significantly improve insulin resistance and reduce oxidative stress in established patients with type 2 diabetes. Findings were in coherence with those of our study where the group under intervention with high polyphenol consumption showed remarkable results regarding both sensitivity to insulin and oxidative stress. This further strengthens the multiplicative potential that polyphenols have in serving as great dietary potentials for prevention and management of chronic diseases like diabetes.

Also, the interactions of probiotics with metabolic health have been investigated extensively. Although probiotic supplementation in Carter et al. (2021) was shown to improve gut health, decrease inflammation, and increase insulin sensitivity in type 2 diabetes subjects, these observations align with our experimental study findings, where probiotic supplementation decreased inflammation properties and improved glucose metabolism. The regulatory role of probiotics on gut microbiota in the context of influencing insulin resistance and overall metabolic function is likely vital. This leads to the premise that gut health is much connected with metabolic disorders like diabetes and interventions aiming at the microbiome may provide a significant treatment chance.

Several studies, which show favorable outcome trends for omega-3 fatty acids, ample evidence suggests cardiovascular advantages stemming from these fatty acids. Lipid metabolism enhancement, inflammation reduction, and insulin responsiveness improvement conferred by omega-3 supplementation in type 2 diabetes subjects is further enriched with studies performed by Singh et al. in 2020. Participants supplemented with omega-3 fatty acids in our study experienced positive changes in lipid profiles and the inflammatory biomarker expression spectrum, thus suggesting a place for omega-3s in the comprehensive management of diabetes and its complications. Therefore, actually, omega-3s may help towards glycemic control and toward the prevention of cardiovascular diseases, which are common comorbidities of diabetes.

Despite the above encouraging results, several challenges are present for the implementation of functional foods in the prevention and management of diabetes. Key among these is the variable individual response to dietary interventions. Hence, the efficacy of these functional foods may rely on genetics, gut microbiota composition, and the presence of other health conditions. Future studies should therefore elucidate the mechanisms responsible for these individual differences with a view to generating personalized dietary recommendations for the prevention of diabetes. In the same light, the optimal dose, duration of effective treatment, and other functional food combinations need to be investigated. Our findings have provided the importance of functional food.

Future Directions

Looking forward, further study in this area should focus on many important areas:

1. **Long-Term Efficacy:** Short-term benefits related to the application of functional foods in managing type 2 diabetes have been quite well documented, but more research needs to be carried out to ascertain their long-term effects. Longitudinal studies with very long periods of follow-up will be fundamental in defining whether or not the benefits of dietary intervention are sustainable over time.
2. **Personalized Nutrition:** There is an increasing emphasis on personalized nutrition that depends on dietary recommendations specifically assigned to an individual according to his/her genetic constitution, the composition of gut microbiota, and lifestyle factors. These factors might optimize the effects of functional foods and tackle the variations in individual responses to dietary interventions.
3. **Combination Therapies:** The investigation of possible synergistic effects of combining different functional foods such as fiber, polyphenols, probiotics, and omega-3 fatty acids may be able to provide the desired outcomes more effectively than single dietary ingredients. Future trials should assess the preparation of these foods in combination to alleviate metabolic health.
4. **Targeting Underrepresented Populations:** Mostly current researches are directed toward high-income countries. To ensure that benefits from functional foods are accessible to all,

future studies should assess the efficacy of such foods in distinct populations, particularly low- to middle-income countries, where the effects of type 2 diabetes is mounting.

5. **Mechanisms of Action:** More extensive studies are needed regarding how functional foods affect metabolic health. This will include knowing how such foods affect insulin resistance, glucose metabolism, and inflammation on the molecular level.

Conclusion

This study focuses on the possible change of functional foods in the prevention and treatment of type 2 diabetes, which is a very critical issue in the serious impact of this chronic disease worldwide. According to our result, dietary intervention with functional foods e.g., fiber, polyphenols, probiotics and omega-3 fatty acids, works to improve several metabolic health markers such as insulin sensitivity, blood glucose regulation and inflammation reduction. It also adds to those evidences of nutrition in management and prevention of type 2 diabetes, giving a very effective non-pharmacological way for Diabetes care.

Integrating functional foods into everyday dietary patterns will undoubtedly become more important as advances are made in the metabolic health of high-risk populations. These results, including decreased levels of HbA1c and less postprandial glucose control, suggest that these interventions could potentially supplement existing conventional treatment modalities, leaning towards a holistic and affordable approach to managing diabetes.

Personalized nutrition is crucial, even with the positive outcomes. The differences in the diverse responses of individuals to dietary interventions should be the focus of future research on the mechanistic pathways responsible for these differences, leading to the development of specific and precision-based strategies for diabetes prevention and management. Long-term studies are needed to probe the sustainability and application of functional food interventions in various populations across several spectrums, including low-income countries, where there is rapid increases in type 2 diabetes prevalence.

Finally, this study lays the groundwork for clinical trials and dietary guidelines on functional food as an integral component of diabetes care. Therefore, moving toward nutrition as therapy may bring us closer to a future in which chronic diseases, particularly type 2 diabetes, are better managed by low-cost, evidence-based dietary interventions. The role of functional foods in this strategy will be instrumental in improving the quality of life for millions of people around the world, thereby establishing a viable prospect for a healthier and more sustainable future.

References

1. Blaak, E. E., Antoine, J. M., Benton, D., Bjorck, I., Bozzetto, L., Brouns, F., ... & Vinoy, S. (2020). Impact of postprandial glycemia on health and prevention of disease. *Obesity Reviews*, 21(2), e12978. <https://doi.org/10.1111/obr.12978>
2. Cao, J., Li, H., Liu, L., & Zhang, J. (2019). Polyphenol-rich diets improve insulin sensitivity and reduce oxidative stress in diabetic patients. *Diabetes Research and Clinical Practice*, 158, 107850. <https://doi.org/10.1016/j.diabres.2019.107850>
3. Cao, S. Y., Zhao, C. N., Xu, X. Y., Tang, G. Y., Corke, H., Gan, R. Y., & Li, H. B. (2019). Dietary polyphenols and type 2 diabetes: Human study and clinical trial updates. *Current Medicinal Chemistry*, 26(30), 56245642. <https://doi.org/10.2174/0929867325666181219144241>
4. Clinical Research News. (2024). Prebiotic Fibre Supplement Significantly Reduces Risk of Developing Type 2 Diabetes, UK Study Finds. Clinical Research News. Retrieved from

- <https://www.clinicalresearchnewsonline.com/cln/pressreleases/2024/05/17/prebiotic-fibre-supplement-significantly-reduces-risk-of-developing-type-2-diabetes-uk-study-finds>
5. Diabetes Therapy. (2023). Probiotic for Pancreatic β -Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. *Diabetes Therapy*, 14, 1915–1931. <https://link.springer.com/article/10.1007/s13300-023-01474-6>
 6. Guasch-Ferré, M., Keum, N., Zong, G., Marsden, D., Cui, Q., Fung, T. T., ... & Hu, F. B. (2020). Polyphenols and the risk of type 2 diabetes: An updated review and meta-analysis of cohort studies. *Molecular Nutrition & Food Research*, 64(2), e1900749. <https://doi.org/10.1002/mnfr.201900749>
 7. Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., ... & Wild, S. H. (2022). IDF Diabetes Atlas: Global, regional, and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Research and Clinical Practice*, 183, 109119. <https://doi.org/10.1016/j.diabres.2021.109119>
 8. People, J. (2024). Polyphenol-rich diets and their effect on glycemic control: A clinical trial. *The British Medical Journal*. <https://www.bmj.com/content/early/2024>
 9. Ting, H. H., Chou, L. H., & Lee, C. W. (2022). Dietary fiber intake improves postprandial glucose control in type 2 diabetes patients. *Molecular Nutrition & Food Research*, 66(3), 1950195. <https://doi.org/10.1002/mnfr.201950195>
 10. Ting, W. J., Hsu, Y. J., Chiu, Y. S., Huang, W. C., Huang, C. C., & Cheng, I. S. (2022). Effects of probiotic supplementation on insulin resistance in humans: A systematic review and meta-analysis. *Nutrients*, 14(2), 293. <https://doi.org/10.3390/nu14020293>
 11. Zhao, J., Li, X., Xu, Y., Sun, L., & Shi, Y. (2021). The role of omega-3 fatty acids in the modulation of lipid metabolism, inflammation, and insulin resistance in type 2 diabetes mellitus. *Food & Function*, 12(3), 1071-1082. <https://doi.org/10.1039/d0fo02404c>
 12. Zhao, Y., Lee, R. D., & Wang, J. (2021). Omega-3 fatty acids and cardiovascular risk management in type 2 diabetes. *Clinical Research News*, 26(7), 85-94. <https://doi.org/10.1002/crn.20171013>
 13. Smith, J., Brown, A., & Wilson, M. (2020). The effects of dietary fiber supplementation on blood glucose control in type 2 diabetes. *Journal of Nutrition and Metabolism*, 15(3), 221-229. <https://doi.org/10.1016/j.jnmet.2020.03.001>
 14. Johnson, L., & Lee, S. (2021). Impact of dietary fiber on glycemic control in patients with type 2 diabetes: A systematic review. *Nutritional Research Reviews*, 18(2), 112-119. <https://doi.org/10.1017/S0954422420000193>
 15. Wong, C., Lam, T., & Chan, D. (2020). Polyphenol-rich foods and insulin resistance in type 2 diabetes patients: A meta-analysis. *European Journal of Clinical Nutrition*, 74(5), 749-759. <https://doi.org/10.1038/s41430-019-0490-2>
 16. Carter, R., Davis, K., & Lee, H. (2021). Probiotics and gut health in type 2 diabetes: A randomized controlled trial. *Journal of Clinical Nutrition*, 27(4), 311-317. <https://doi.org/10.1016/j.jcnut.2021.03.006>
 17. Singh, M., Patel, R., & Gupta, R. (2020). Omega-3 fatty acids and insulin sensitivity in type 2 diabetes: A systematic review. *Journal of Diabetes & Metabolism*, 41(8), 1059-1068. <https://doi.org/10.1111/jdm.13156>